In the possible event of a pandemic, the UK has secured 5 million doses of an H5 influenza vaccine to stay one step ahead of the avian influenza virus.
Soraiya Verjee, Business Development Director of Sea Monster, discusses how the use of games and animation can combat COVID-19 and vaccine misinformation.
According to a new study, by researchers at the University of Zurich, more than a quarter of COVID-19 patients report being symptomatic 6-8 months after infection.
The London Medical Laboratory has voiced its concerns about Freedom Day as the Government's decision to end restrictions is based on the wrong data and could land us in another lockdown.
Arthur Goudena, Marketing Manager of PHC Europe, explains how the company’s cold storage solutions are available to support COVID-19 vaccination campaigns across Europe.
Michelle Davis, Head of External Relations at Malaria Consortium, shares with us what we need to know about learning from COVID-19 and the continuing fight against malaria.
Arthur Lupia with Deborah H. Olster from the Directorate for Social, Behavioral and Economic Sciences at the U.S. National Science Foundation, explain the power of international collaboration when it comes to social and behavioural science responding to COVID-19.
The Canadian Institutes of Health Research, part of the Government of Canada, has an Institute of Infection and Immunity. Here, we gain a flavour of what they do.
Open Access Government caught up with Dr Mary Stephen, Public Health Expert at the World Health Organization African Region, provides an update on the COVID-19 outbreak in Africa.
Chairs of the Parliament’s Coalition for Mental Health and Wellbeing demand immediate action to address the growing mental health crisis and the creation of a long-term Mental Health Strategy.
Here, we interview Alex Wilson, Co-founder of specialist reagent company PCR Biosystems, discussing how their expertise in enzyme development and large-scale production has been successfully applied to COVID-19 testing solutions around the world.
The Medicines and Healthcare products Regulatory Agency (MHRA) has concluded that the Pfizer/BioNTech COVID-19 vaccine is safe to use in 12-15-year-olds.
